Welcome to the international HTA database

Showing [22099 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Asfotase alfa (hypophosphatasia) - Benefit assessment according to §35a Social Code Book V]
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Guidelines for safe surgery: open versus laparoscopic. A rapid review commissioned by RACS
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Optimal use of immunoglobulins in hematology]
2020	Swiss Federal Office of Public Health (FOPH)	Vitamin D testing
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Larotrectinib (solid tumours) - Benefit assessment according to §35a Social Code Book V]
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Guidelines for personal protective equipment. A rapid review comissioned by RACS
2020	NIHR Health Technology Assessment programme	Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Optimal use of immunoglobulins in clinical immunology]
2020	Canary Health Service	[Transcranial magnetic stimulation for the treatment of cocaine addiction]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Services and Delivery Research programme	Optimising acute care for people with dementia: a mixed-methods study
2020	Institute for Clinical and Economic Review (ICER)	Supervised injection facilities and other supervised consumption sites: effectiveness and value
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volumes of services and quality of treatment outcome in the surgical treatment of breast cancer - rapid report]
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: use of sedation and general anesthesia in pediatric dental care]
2020	Canary Health Service	[Physical exercise intervention in older hospitalized patients for the prevention of functional and cognitive deterioration during hospital admission]
2020	Institute for Clinical and Economic Review (ICER)	Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Addendum to Commission A19-59]
2020	NIHR Health Technology Assessment programme	Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT
2020	NIHR Health Services and Delivery Research programme	Dementia and cognitive impairment in the older prison population of England and Wales: identifying individual need and developing a skilled, multi-agency workforce to deliver targeted and responsive services
2020	Canary Health Service	Seguridad, efectividad clínica y coste-efectividad de intervenciones para la prevención del delirium en el ingreso hospitalario
2020	Institute for Clinical and Economic Review (ICER)	Digital health technologies as an adjunct to medication assisted therapy for opioid use disorder
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dolutegravir/lamivudine (HIV infection) - Addendum to Commission A19-55]
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: the therapeutic value of hyperbaric oxygen (HBO) on children with cerebral palsy]
2020	Canary Health Service	Efectividad, seguridad y coste-efectividad de los sistemas de monitorización continua de glucosa intersticial en tiempo real (MCG-TR) para la diabetes mellitus tipo 1 y 2. Actualización
2020	Institute for Clinical and Economic Review (ICER)	Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55]
2020	NIHR Health Technology Assessment programme	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Genetic testing in the context of familial hypercholesterolaemia management. Organisational and ethical implications (part 1), and economic aspects (part 2)
2020	Canary Health Service	Seguridad, efectividad y coste-efectividad de los sistemas integrados de infusión subcutánea continua de insulina más sensor de monitorización continua de glucosa
2020	Institute for Clinical and Economic Review (ICER)	Targeted immune modulators for ulcerative colitis: effectiveness and value
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ramucirumab (hepatocellular carcinoma) - Addendum to Commission A19-73]
2020	Austrian Institute for Health Technology Assessment (AIHTA)	[Lung cancer screening in risk groups]
2020	Canary Health Service	Cribado neonatal de la inmunodeficiencia combinada grave: análisis coste-efectividad
2020	Institute for Clinical and Economic Review (ICER)	Modulator treatments for cystic fibrosis: effectiveness and value
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dupilumab (atopic dermatitis in adolescents) - Addendum to Commission A19-75]
2020	NIHR Health Technology Assessment programme	High-dose oral vitamin D supplementation and mortality in people aged 65 84 years: the VIDAL cluster feasibility RCT of open versus double-blind individual randomisation
2020	NIHR Health Services and Delivery Research programme	Access to primary and community health-care services for people 16 years and over with intellectual disabilities: a mapping and targeted systematic review
2020	Basque Office for Health Technology Assessment (OSTEBA)	[Efficacy and safety of mechanical thrombectomy in the treatment of patients with ischaemic stroke beyond 6 hours after onset or with an unknown time of onset]
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Lung cancer screening in risk groups: a review-update of the economic evidence (Part II)
2020	Institute for Clinical and Economic Review (ICER)	Alternative pricing models for remdesivir and other potential treatments for COVID-19
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, homozygous) - Addendum to Commission A19-70]
2020	Health Information and Quality Authority (HIQA)	Evidence summary for natural history of COVID-19 in children
2020	Basque Office for Health Technology Assessment (OSTEBA)	[Neonatal hearing screening programmes: A systematic review of economic evaluation studies and descriptive analysis of Spanish regional programmes]
2020	Ontario Health	Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis at Low Surgical Risk
2020	Canary Health Service	[Radiofrequency ablation for metastatic spinal lesions]
2020	Institute for Clinical and Economic Review (ICER)	Acute treatments for migraine
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Addendum to Commission A19-65]
2020	Health Information and Quality Authority (HIQA)	Evidence summary for average length of stay in the intensive care unit for COVID-19
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (combination with tezacaftor/ivacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Addendum to Commission A19-71]
2020	Health Information and Quality Authority (HIQA)	Evidence summary for COVID-19 clinical samples
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: protecting health care workers' (HCW) families at home
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Andexanet alfa (acute major bleeding) - Addendum to Commission A19-76]
2020	Health Information and Quality Authority (HIQA)	Evidence summary for asymptomatic transmission of COVID-19
2020	Ontario Health	Automated CT perfusion imaging to aid in the selection of patients with acute ischemic stroke for mechanical thrombectomy
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[CD34+ cells (beta thalassaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Health Information and Quality Authority (HIQA)	Rapid health technology assessment of alternative diagnostic testing approaches for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
2020	Ontario Health	Home narrowband ultraviolet B phototherapy for photoresponsive skin conditions
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Mandibular advancement devices in mild to moderate obstructive sleep apnoea in adults]
2020	Health Information and Quality Authority (HIQA)	Evidence summary of placental transfer of antibodies
2020	Ontario Health	Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: corticosteroids for hospitalized patients
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Belimumab (SLE) - Benefit assessment according to §35a Social Code Book V]
2021	Scottish Medicines Consortium (SMC)	Fostamatinib treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments
2021	Health Information and Quality Authority (HIQA)	Rapid review of public health guidance on protective measures for vulnerable groups in the context of COVID-19
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2021	Scottish Medicines Consortium (SMC)	Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
2021	Health Technology Wales (HTW)	Strategies for Relatives (START) intervention to improve the mental health of carers of people with dementia
2021	Health Information and Quality Authority (HIQA)	Rolling summary of the evidence in relation to the Omicron (B.1.1.529) variant
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (urothelial carcinoma first line treatment) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021	NIHR Health Technology Assessment programme	A comparison of general anaesthesia versus awake-regional anaesthesia in infancy: an international, multicentre, randomised controlled equivalence trial; the GAS study
2021	Belgian Health Care Knowledge Centre (KCE)	Remote monitoring of patients with cardiovascular implantable electronic devices: a health technology assessment (update of the KCE Report 136)
2021	Health Information and Quality Authority (HIQA)	Use of respirator masks by persons who are at higher risk from COVID-19
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021	Health Council of the Netherlands Gezondheidsraad (GR)	[Influenza vaccination: review of indications]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: Rebinyn (nonacog beta pegol) – Type B hemophilia (re-evaluation)]
2021	Health Information and Quality Authority (HIQA)	Rapid review of public health guidance for residential care facilities in the context of COVID-19
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fostemsavir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Long COVID care pathways: a systematic review
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Avatrombopag (primary chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2021	Center for Drug Evaluation (CDE)	Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sodium zirconium cyclosilicate (hyperkalaemia) - Benefit assessment according to §35a Social Code Book V]
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Autologous hematopoietic cell transplant for patients with multiple sclerosis
2021	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Percutaneous repair systems for tricuspid valve insufficiency by annuloplasty]
2021	Adelaide Health Technology Assessment (AHTA)	Guidelines for preparing assessments for the Medical Services Advisory Committee. Version 1.0
2021	Center for Drug Evaluation (CDE)	Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C-A population-based cohort study
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Avatrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2021	Health Technology Wales (HTW)	Oscillating positive expiratory pressure devices for airway clearance in chronic hypersecretory lung conditions
2021	Adelaide Health Technology Assessment (AHTA)	Immunoglobulin for chronic inflammatory demyelinating polyneuropathy
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V]
2021	NIHR Health Technology Assessment programme	Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review
2021	Adelaide Health Technology Assessment (AHTA)	Genomic testing for the diagnosis of heritable cardiomyopathies
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bedaquiline (multidrug resistant tuberculosis: children aged 5 to 11 years) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021	Norwegian Institute of Public Health (NIPH)	[Hysterectomy for heavy menstrual bleeding: rapid health technology assessment]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality for TAVI]
2021	Andalusian Health Technology Assessment Area (AETSA)	[18F-FDG in myocardial viability for revascularization]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial nutrition in acute pancreatitis]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial tube feeding in acute pancreatitis]
2021	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V - Addendum to commission H20-05]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Prostate cancer; does the use of fusion biopsy lead to better treatment results compared to the use of conventional diagnostic procedures?]